CO6670529A2 - Sistema de suministro de buprenorfina de liberación sostenida - Google Patents
Sistema de suministro de buprenorfina de liberación sostenidaInfo
- Publication number
- CO6670529A2 CO6670529A2 CO13001795A CO13001795A CO6670529A2 CO 6670529 A2 CO6670529 A2 CO 6670529A2 CO 13001795 A CO13001795 A CO 13001795A CO 13001795 A CO13001795 A CO 13001795A CO 6670529 A2 CO6670529 A2 CO 6670529A2
- Authority
- CO
- Colombia
- Prior art keywords
- sustained release
- buprenorphine
- delivery system
- release system
- metabolite
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1009549.5A GB2481018B (en) | 2010-06-08 | 2010-06-08 | Injectable flowable composition comprising buprenorphine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6670529A2 true CO6670529A2 (es) | 2013-05-15 |
Family
ID=42471306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13001795A CO6670529A2 (es) | 2010-06-08 | 2013-01-04 | Sistema de suministro de buprenorfina de liberación sostenida |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US8921387B2 (https=) |
| EP (3) | EP3360538B1 (https=) |
| JP (2) | JP5986072B2 (https=) |
| KR (1) | KR101865689B1 (https=) |
| CN (1) | CN103079544B (https=) |
| AU (1) | AU2011263478B2 (https=) |
| BR (1) | BR112012031290A2 (https=) |
| CA (1) | CA2801676C (https=) |
| CL (1) | CL2012003462A1 (https=) |
| CO (1) | CO6670529A2 (https=) |
| CY (1) | CY1120761T1 (https=) |
| DK (2) | DK3360538T3 (https=) |
| ES (2) | ES2939612T3 (https=) |
| FI (1) | FI3360538T3 (https=) |
| GB (2) | GB2513267B (https=) |
| HR (1) | HRP20180118T1 (https=) |
| HU (1) | HUE038275T2 (https=) |
| IL (2) | IL223488A (https=) |
| LT (1) | LT2579874T (https=) |
| MX (1) | MX339209B (https=) |
| MY (1) | MY171625A (https=) |
| NO (1) | NO2579874T3 (https=) |
| NZ (1) | NZ604026A (https=) |
| PL (1) | PL2579874T3 (https=) |
| PT (1) | PT2579874T (https=) |
| RS (1) | RS56820B1 (https=) |
| RU (1) | RU2607498C2 (https=) |
| SG (1) | SG186200A1 (https=) |
| SI (1) | SI2579874T1 (https=) |
| SM (1) | SMT201800038T1 (https=) |
| WO (1) | WO2011154724A2 (https=) |
| ZA (1) | ZA201209233B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8470359B2 (en) | 2000-11-13 | 2013-06-25 | Qlt Usa, Inc. | Sustained release polymer |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| GB2513267B (en) | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
| WO2013126552A1 (en) | 2012-02-21 | 2013-08-29 | Auburn University | Buprenorphine nanoparticle composition and methods thereof |
| KR102082529B1 (ko) | 2012-04-17 | 2020-02-27 | 퍼듀 퍼머 엘피 | 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법 |
| HRP20210068T1 (hr) * | 2012-07-26 | 2021-03-05 | Camurus Ab | Opioidne formulacije |
| WO2014016428A1 (en) * | 2012-07-26 | 2014-01-30 | Camurus Ab | Opioid formulations |
| WO2014093907A1 (en) * | 2012-12-13 | 2014-06-19 | A.P. Pharma, Inc. | Pharmaceutical composition comprising antiemetic compounds and polyorthoester |
| US9393211B2 (en) | 2013-03-15 | 2016-07-19 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| US9636308B2 (en) | 2013-03-15 | 2017-05-02 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| US9592227B2 (en) * | 2013-03-15 | 2017-03-14 | Heron Therapeutics, Inc. | Compositions of a polyorthoester and an aprotic solvent |
| GB201404139D0 (en) * | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| US9801945B2 (en) | 2014-04-21 | 2017-10-31 | Heron Therapeutics, Inc. | Long-acting polymeric delivery systems |
| WO2018048460A1 (en) | 2014-04-21 | 2018-03-15 | Heron Therapeutics, Inc. | A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam |
| DK3134070T3 (da) * | 2014-04-21 | 2020-12-21 | Heron Therapeutics Inc | Sammensætninger af en polyorthoester og en organisk syre-excipiens |
| PT3134068T (pt) | 2014-04-21 | 2021-10-18 | Heron Therapeutics Inc | Sistemas de libertação poliméricos de longa duração |
| PL3137081T3 (pl) | 2014-04-28 | 2018-06-29 | Orphomed, Inc. | Dimer buprenorfiny i jego zastosowanie w leczeniu chorób układu pokarmowego |
| GB201419091D0 (en) * | 2014-10-27 | 2014-12-10 | Camurus Ab | Formulations |
| CA3015557C (en) | 2014-11-07 | 2019-07-16 | Indivior Uk Limited | The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders |
| JP6949820B2 (ja) * | 2015-08-03 | 2021-10-13 | トルマー インターナショナル リミテッド | 薬物の持続投与のための液体ポリマー送達システム |
| US20200155449A1 (en) | 2015-11-16 | 2020-05-21 | Medincell | Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue |
| SG11201901294QA (en) | 2016-09-13 | 2019-03-28 | Alar Pharmaceuticals Inc | Sustained-release buprenorphine formulations background of invention |
| AU2018283724B2 (en) | 2017-06-16 | 2021-08-19 | Indivior Uk Limited | Methods to treat opioid use disorder |
| US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
| WO2019144079A1 (en) | 2018-01-22 | 2019-07-25 | Yuhua Li | Pharmaceutical composition for sustained release delivery of buprenorphine |
| AR117426A1 (es) * | 2018-05-11 | 2021-08-04 | Alar Pharmaceuticals Inc | Formulaciones inyectables de acción prolongada y formas cristalinas de derivados de buprenorfina |
| IL282120B2 (en) | 2018-10-11 | 2025-08-01 | Indivior Uk Ltd | Buprenorphine to treat respiratory depression |
| US12403291B2 (en) | 2019-08-30 | 2025-09-02 | Intersect Ent, Inc. | Submucosal bioresorbable drug eluting platform |
| CN118831057A (zh) * | 2023-04-25 | 2024-10-25 | 深圳善康医药科技股份有限公司 | 丁丙诺啡植入剂及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| JP4259610B2 (ja) | 1994-04-08 | 2009-04-30 | キューエルティー・ユーエスエイ・インコーポレーテッド | 液体デリバリー組成物 |
| US20030211157A1 (en) * | 1996-05-06 | 2003-11-13 | Simon David Lew | Semi-sol delivery blend for water soluble molecules |
| US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| US6143314A (en) * | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| SI2561860T1 (en) * | 2002-05-31 | 2018-05-31 | Titan Pharmaceuticals, Inc. | An implantable polymeric device for prolonged release of buprenorphine |
| RU2355385C2 (ru) * | 2002-11-06 | 2009-05-20 | Алза Корпорейшн | Композиции пролонгированного действия с контролируемым высвобождением |
| JP2007525429A (ja) * | 2003-03-11 | 2007-09-06 | キューエルティー ユーエスエー，インコーポレイテッド． | 細胞スケジュール依存性抗癌剤のための処方 |
| MX2007003789A (es) * | 2004-10-04 | 2007-07-20 | Qlt Usa Inc | Suministro ocular de formulaciones polimericas para suministro. |
| RS53890B1 (sr) * | 2004-11-10 | 2015-08-31 | Tolmar Therapeutics, Inc. | Stabilizovan polimerni sistem za isporuku |
| DK3660073T3 (da) | 2007-02-15 | 2023-09-18 | Tolmar International Ltd | Poly(lactid-co-glycolid) med lav sprængning |
| US20090181068A1 (en) * | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
| GB2513267B (en) | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
-
2010
- 2010-06-08 GB GB1413064.5A patent/GB2513267B/en active Active
- 2010-06-08 GB GB1009549.5A patent/GB2481018B/en active Active
-
2011
- 2011-06-06 DK DK17205986.7T patent/DK3360538T3/da active
- 2011-06-06 EP EP17205986.7A patent/EP3360538B1/en active Active
- 2011-06-06 EP EP23150636.1A patent/EP4218720A1/en active Pending
- 2011-06-06 RU RU2012157244A patent/RU2607498C2/ru not_active IP Right Cessation
- 2011-06-06 DK DK11728037.0T patent/DK2579874T3/da active
- 2011-06-06 CA CA2801676A patent/CA2801676C/en active Active
- 2011-06-06 NZ NZ604026A patent/NZ604026A/en unknown
- 2011-06-06 ES ES17205986T patent/ES2939612T3/es active Active
- 2011-06-06 MX MX2012014335A patent/MX339209B/es active IP Right Grant
- 2011-06-06 BR BR112012031290A patent/BR112012031290A2/pt not_active Application Discontinuation
- 2011-06-06 SI SI201131401T patent/SI2579874T1/en unknown
- 2011-06-06 KR KR1020127032282A patent/KR101865689B1/ko not_active Expired - Fee Related
- 2011-06-06 PT PT117280370T patent/PT2579874T/pt unknown
- 2011-06-06 LT LTEP11728037.0T patent/LT2579874T/lt unknown
- 2011-06-06 WO PCT/GB2011/051057 patent/WO2011154724A2/en not_active Ceased
- 2011-06-06 NO NO11728037A patent/NO2579874T3/no unknown
- 2011-06-06 PL PL11728037T patent/PL2579874T3/pl unknown
- 2011-06-06 HU HUE11728037A patent/HUE038275T2/hu unknown
- 2011-06-06 AU AU2011263478A patent/AU2011263478B2/en active Active
- 2011-06-06 SM SM20180038T patent/SMT201800038T1/it unknown
- 2011-06-06 FI FIEP17205986.7T patent/FI3360538T3/fi active
- 2011-06-06 CN CN201180039223.3A patent/CN103079544B/zh not_active Expired - Fee Related
- 2011-06-06 RS RS20180068A patent/RS56820B1/sr unknown
- 2011-06-06 JP JP2013513755A patent/JP5986072B2/ja not_active Expired - Fee Related
- 2011-06-06 ES ES11728037.0T patent/ES2656938T3/es active Active
- 2011-06-06 HR HRP20180118TT patent/HRP20180118T1/hr unknown
- 2011-06-06 MY MYPI2012005274A patent/MY171625A/en unknown
- 2011-06-06 US US13/703,013 patent/US8921387B2/en active Active
- 2011-06-06 SG SG2012089652A patent/SG186200A1/en unknown
- 2011-06-06 EP EP11728037.0A patent/EP2579874B1/en active Active
-
2012
- 2012-12-06 IL IL223488A patent/IL223488A/en active IP Right Grant
- 2012-12-06 ZA ZA2012/09233A patent/ZA201209233B/en unknown
- 2012-12-07 CL CL2012003462A patent/CL2012003462A1/es unknown
-
2013
- 2013-01-04 CO CO13001795A patent/CO6670529A2/es unknown
-
2016
- 2016-06-01 JP JP2016110259A patent/JP6251774B2/ja active Active
-
2017
- 2017-09-11 IL IL254417A patent/IL254417A0/en unknown
-
2018
- 2018-01-24 CY CY181100098T patent/CY1120761T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6670529A2 (es) | Sistema de suministro de buprenorfina de liberación sostenida | |
| BR112012031288A2 (pt) | composições | |
| ECSP13012611A (es) | Derivados de pirazol-aminopirimidina como moduladores de la lrrk2 | |
| CR20120190A (es) | INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA | |
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| MX2014012695A (es) | Derivados de isoindolona. | |
| CR20110110A (es) | Composicion farmaceutica | |
| CY1117603T1 (el) | Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2 | |
| MX2013011086A (es) | (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas. | |
| TN2012000392A1 (en) | Oral formulations and lipophilic salts of methylnaltrexone | |
| MX353024B (es) | Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia. | |
| WO2011140232A3 (en) | Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents | |
| BRPI1015983A2 (pt) | composto, uso do composto, método para tratar um paciente, e, composição farmacêutica. | |
| CL2011001768A1 (es) | Compuestos derivados de ciclopentanodiona; procesos para la preparacion de dichos compuestos; composicion herbicida; metodo para el control de pastos y malezas en cultivos de plantas utiles; y compuesto intermediario. | |
| MX2012003324A (es) | Compuesto de glicina. | |
| WO2011017054A3 (en) | Prodrugs of desazadesferrothiocin polyether analogues as metal chelation agents | |
| BRPI0920042A2 (pt) | uso de um composto, dispositivo médico implantável, método para a sua fabricação, e, método in vitro para exterminar, inibir ou prevenir o crescimento de um biofilme microbiano. | |
| WO2012168885A3 (en) | Bisacodyl and its analogues as drugs for use in the treatment of cancer | |
| EP2666773A8 (en) | Organic amine salts of azilsartan, preparation method and use thereof | |
| BRPI0920251A2 (pt) | composto, composição famacêutica, formulação, métodos para preparar o composto, um sal farmaceuticamente aceitável, para inibir o crescimento de um micróbio, para tratar um mamífero tendo uma infecção microbiana, e, uso de um composto. | |
| BR112012013199A2 (pt) | composto, composição farmacêutica, e , uso de um composto | |
| MX2013006564A (es) | Uso de dronedarona para la preparacion de un farmaco para uso en la gestion del riesgo de daño hpatico. | |
| EP2692723A8 (en) | Aryloxy dihalopropenyl ether compound and use thereof | |
| TN2014000060A1 (en) | Benzothiazolone compound | |
| WO2012078051A3 (en) | IPN Vaccine |